10-Sep-2026
No headlines found.
LB Pharmaceuticals to Participate in Upcoming September Investor Events
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
LB Pharmaceuticals Announces $150 Million Private Placement
Globe Newswire (Wed, 29-Jul 8:00 AM ET)
Globe Newswire (Wed, 22-Jul 8:00 AM ET)
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 10-Jul 4:38 PM ET)
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
Globe Newswire (Tue, 30-Jun 8:00 AM ET)
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LB Pharmaceuticals trades on the NASDAQ stock market under the symbol LBRX.
As of September 10, 2026, LBRX stock price declined to $46.25 with 171,917 million shares trading.
LBRX has a beta of 1.38, meaning it tends to be more sensitive to market movements. LBRX has a correlation of 0.11 to the broad based SPY ETF.
LBRX has a market cap of $1.49 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that LBRX belongs to (by Net Assets): VTI, VXF, XPH, SCHA, VTWO.
LBRX support price is $46.02 and resistance is $49.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LBRX shares will trade within this expected range on the day.